Stockscreener 앱 받기
142.73
1.30%
1.83
시간 외 거래:
142.75
0.02
+0.01%
전일 마감가:
$140.90
열려 있는:
$141.67
하루 거래량:
610.88K
Relative Volume:
0.71
시가총액:
$14.16B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
48.38
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+1.05%
1개월 성능:
+7.40%
6개월 성능:
+28.01%
1년 성능:
+16.70%
1일 변동 폭
$141.18
$143.39
1주일 범위
$139.25
$144.04
52주 변동 폭
$84.23
$154.61
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
142.73 | 13.97B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
146.93 | 65.35B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.09 | 47.75B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.40 | 41.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.38 | 21.43B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
403.68 | 18.00B | 2.99B | 1.21B | 1.13B | 25.06 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences’ SWOT analysis: stock outlook amid pipeline progress, IRA challenges - Investing.com
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Voya Investment Management LLC - MarketBeat
Fed Watch: Why is Neurocrine Biosciences Inc stock going upJuly 2025 Highlights & Reliable Volume Spike Alerts - خودرو بانک
Woodline Partners LP Buys Shares of 132,892 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to present new phase 2 data for depression treatment - Investing.com India
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 - WV News
First-in-Class AMPA-PAM Depression Treatment: Neurocrine's Osavampator Phase 2 Results at Major Conference - Stock Titan
What Does Wall Street Think About Neurocrine Biosciences (NBIX)? - uk.finance.yahoo.com
Moving Averages: Is Neurocrine Biosciences Inc stock forming a triangle patternQuarterly Profit Review & Free High Accuracy Swing Entry Alerts - خودرو بانک
Juncture Wealth Strategies LLC Sells 2,766 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Volatility Watch: How cyclical is Neurocrine Biosciences Incs revenue streamWeekly Loss Report & Daily Risk Controlled Trade Plans - خودرو بانک
City Center Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
First Hawaiian Bank Trims Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Swedbank AB Has $47.52 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Performance Recap: What are Neurocrine Biosciences Incs growth leversWeekly Trade Analysis & Breakout Confirmation Trade Signals - خودرو بانک
Intech Investment Management LLC Has $3.96 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
United Services Automobile Association Buys Shares of 6,547 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Integrated Wealth Concepts LLC Buys 4,526 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Plato Investment Management Ltd Has $255,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Teza Capital Management LLC Has $587,000 Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Amundi Sells 30,673 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Jacobs Levy Equity Management Inc. - MarketBeat
Great Lakes Advisors LLC Has $3.54 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Vident Advisory LLC Invests $202,000 in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Update - MarketBeat
Parkman Healthcare Partners LLC Buys 52,655 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Getting In Cheap On Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Might Be Difficult - 富途牛牛
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Alyeska Investment Group L.P. - MarketBeat
EFG Asset Management North America Corp. Has $1.12 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Baird Financial Group Inc. Buys 3,103 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Fibonacci Support Holding Strong in Neurocrine Biosciences Inc.July 2025 Trends & Weekly Chart Analysis and Guides - beatles.ru
Federation des caisses Desjardins du Quebec Lowers Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Palo Alto Investors LP Invests $1.48 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc. recovery potential after sell offJuly 2025 Momentum & Community Consensus Picks - Newser
Tick level data insight on Neurocrine Biosciences Inc. volatilityLong Setup & Entry Point Confirmation Signals - Newser
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Trexquant Investment LP - MarketBeat
Is Neurocrine Biosciences Inc. benefiting from interest rate changesEarnings Overview Summary & Low Risk Entry Point Tips - خودرو بانک
Can Neurocrine Biosciences Inc. generate free cash flowJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - خودرو بانک
Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Macro Moves & Safe Entry Momentum Tips - Newser
Neurocrine Biosciences: RBC Capital maintains Outperform, raises PT to $149. - AInvest
Neurocrine Bio. stock price target raised to $149 by RBC Capital - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating - MarketScreener
Armistice Capital LLC Acquires 108,190 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What’s next for Neurocrine Biosciences Inc. stock priceWeekly Profit Summary & Reliable Intraday Trade Alerts - Newser
Will Neurocrine Biosciences Inc. benefit from current market trendsMarket Growth Review & Weekly Consistent Profit Watchlists - خودرو بانک
Will Neurocrine Biosciences Inc. price bounce be sustainable2025 Key Lessons & Long-Term Capital Growth Strategies - Newser
Is Neurocrine Biosciences Inc. a cyclical or defensive stockJuly 2025 Breakouts & Weekly Return Optimization Alerts - خودرو بانک
Will Neurocrine Biosciences Inc. stock go up soonJuly 2025 Volume & Community Consensus Picks - Newser
Neurocrine at Cantor Global Healthcare Conference: Strategic Insights on Growth - Investing.com Canada
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
1.07%
자본화:
|
볼륨(24시간):